Tag: Influenza Vaccine
-
PEI Urges Flu Shots Despite Uncertainty Over H3N2 Strain
Public Health Advises Flu Vaccination Amid H3N2 Uncertainty As the flu season arrives on Prince Edward Island, health officials are emphasizing the importance of getting the influenza vaccine even as experts monitor a potentially evolving H3N2 strain. Dr. Heather Morrison, P.E.I.’s chief public health officer, recently stressed that vaccination remains the best available protection against…
-
Health officials urge Islanders to get flu shots amid uncertainty around developing H3N2 strain
Public Health Message: Get Your Flu Shot This Season With the influenza season underway in Prince Edward Island, health officials are urging residents to roll up their sleeves for a flu shot. While vaccines are continually updated to match circulating strains, experts acknowledge uncertainty around how well the current H3N2 component will protect against a…
-
Should I Still Get the Flu Shot If It Isn’t a Perfect Match This Year? Here’s Why It Still Helps
Understanding the question: Is the flu shot worth it if the match isn’t perfect? Many people hear that a flu vaccine isn’t a perfect match for the circulating virus in a given year and wonder whether the annual shot is worth it. The short answer: yes. The full story is more nuanced. Vaccine effectiveness can…
-
Apriori Bio and A*STAR Infectious Diseases Labs Forge Strategic Partnership to Advance Next-Generation Influenza Vaccines
Strategic Partnership to Accelerate Next-Generation Influenza Vaccines Apriori Bio, a Flagship Pioneering company dedicated to developing prospective, variant-resilient vaccines, has announced a strategic collaboration with the Agency for Science, Technology and Research (A*STAR) Infectious Diseases Labs. This partnership aims to accelerate the discovery and development of next-generation influenza vaccines capable of addressing evolving strains and…
-
Apriori Bio and A*STAR Infectious Diseases Labs Forge Partnership to Accelerate Next-Generation Influenza Vaccines
Strategic collaboration set to redefine influenza vaccine development The life sciences landscape received a notable boost as Apriori Bio, a Flagship Pioneering venture focused on variant-resilient vaccines, and the Agency for Science, Technology and Research (A*STAR) Infectious Diseases Labs announced a strategic partnership aimed at accelerating the development of next-generation influenza vaccines. Announced from Cambridge,…
-
How BC’s Respiratory Illness Season Is Shaping Up This Year
What this respiratory illness season might look like in British Columbia As fall settles in, British Columbians are again navigating a familiar mix: sniffles, coughs, and the familiar chorus of notices about respiratory illnesses. Health officials emphasize that while seasonality is predictable, the exact mix of influenza, RSV, and other respiratory pathogens can vary from…
-
Particles that Boost mRNA Delivery Could Lower Vaccine Doses and Costs
New Particle Design Aims to Make mRNA Vaccines More Efficient Scientists at MIT have developed a novel delivery particle that could enhance how mRNA vaccines are presented to the immune system. In preclinical studies, the researchers show that an optimized lipid nanoparticle (LNP) can improve the efficiency with which mRNA is delivered into cells, potentially…
-
MIT lipid nanoparticle boosts mRNA vaccine efficacy
Overview A new lipid nanoparticle delivery particle developed at MIT could transform how mRNA vaccines are delivered, potentially improving effectiveness while reducing the amount of active ingredient needed per dose. The research, described in early-stage studies, centers on refining the particle that ferries the mRNA into cells, a crucial step in vaccine performance. What the…
-
BlueWillow Biologics Demonstrates Promising Intranasal Bird Flu Vaccine in Nature Communications Study
BlueWillow’s Intranasal Bird Flu Vaccine: A Potential Game-Changer in Influenza Prevention BlueWillow Biologics, Inc., a clinical-stage biotech company at the forefront of intranasal vaccine technology, announced compelling results from a peer‑reviewed Nature Communications study. The research highlights the potential of the company’s intranasal bird flu vaccine to elicit robust mucosal and systemic immune responses, a…
-
CSL Seqirus Highlights 14 Abstracts at ESWI 2025: Advancing Enhanced Seasonal Influenza Vaccines
CSL Seqirus to Present 14 Abstracts at ESWI 2025 CSL Seqirus, a global leader in influenza vaccines, announced it will present 14 abstracts at the European Scientific Working group on Influenza (ESWI) conference, taking place in Valencia from 20 to 23 October 2025. The presentations highlight the value of enhanced seasonal influenza vaccines and reinforce…